CytoMed files H1 2025 interim results on Form 6-K

Accepted by SEC EDGAR 09/30/2025 - 07:00 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

CytoMed Therapeutics Limited furnished a Form 6-K providing its unaudited interim condensed consolidated financial statements for the six months ended June 30, 2025, together with management’s discussion and analysis of financial condition and results of operations for the same period.

The company also scheduled a Zoom conference call for the investment community on October 2, 2025 at 10 a.m. ET to discuss these financial results.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What period does CytoMed Therapeutics (GDTC) cover in this Form 6-K?

The Form 6-K covers unaudited interim condensed consolidated financial statements and related management’s discussion and analysis for the six months ended June 30, 2025.

What key documents are included in CytoMed Therapeutics (GDTC) June 30, 2025 Form 6-K?

The filing includes two main exhibits: Exhibit 99.1 with the unaudited interim condensed consolidated financial statements for the six months ended June 30, 2025, and Exhibit 99.2 with the management’s discussion and analysis of financial condition and results of operations for the same period.

Is CytoMed Therapeutics (GDTC) holding a call to discuss the June 30, 2025 results?

Yes. A Zoom conference call to discuss the company’s financial results is scheduled for October 2, 2025 at 10 a.m. ET, and can be accessed via the Zoom link provided in the filing.

Who signed the CytoMed Therapeutics (GDTC) Form 6-K for the period ended June 30, 2025?

The Form 6-K was signed on behalf of the company by CHOO Chee Kong, who is identified as Director and Chairman.

What is the purpose of this CytoMed Therapeutics (GDTC) Form 6-K submission?

The submission is intended to furnish interim financial information, specifically the unaudited interim condensed consolidated financial statements and the management’s discussion and analysis for the six months ended June 30, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Financial Period Ended 30 Jun 2025

Commission File Number: 001-41677

CytoMed Therapeutics Limited

(Exact name of registrant as specified in its charter)

1 Commonwealth Lane

#08-22

Singapore 149544

(Address of Principal Executive Office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F Yes ☒ No ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Yes ☐ No ☒

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): Yes ☐ No ☒

INFORMATION CONTAINED IN THIS FORM 6-K REPORT

CytoMed Therapeutics Limited (the “Company”) is hereby furnishing this report on Form 6-K (the “Report”) to provide the Unaudited Interim Condensed Consolidated Financial Statements of the Company for the six months ended June 30, 2025, included as Exhibit 99.1 of this Report, and the Management’s Discussion and Analysis of Financial Condition and Results of Operations for the six months ended June 30, 2025, included as Exhibit 99.2 of this Report.

Conference Call Information

A conference call to discuss the Company’s financial results via Zoom is scheduled for October 2, 2025 at 10 a.m. ET. The investment community may participate in the conference call by tuning into the following Zoom:

https://us06web.zoom.us/j/86967286296?pwd=Xls7XQsRWteN6eXpgRrkqajaL35aHX.1

Exhibits

Exhibit No.		Description
99.1		Unaudited Interim Condensed Consolidated Financial Statements for the Six Months Ended June 30, 2025
99.2		Management’s Discussion and Analysis of Financial Condition and Results of Operations for the Six Months Ended June 30, 2025

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CytoMed Therapeutics Limited
	By:	/s/ CHOO Chee Kong
	Name:	CHOO Chee Kong
Date: September 30, 2025	Title:	Director and Chairman